HONG KONG – Seoul, South Korea-based SN Bioscience Inc. has developed a drug delivery technology to make injecting antitumor drugs into human bodies possible. Two months after it secured KRW5 billion (US$4.4 million) from South Korea's energy and chemical giant, OCI Co., in a series A financing, the firm is expecting another investment of $3.5 million in the coming weeks. The funding will help it spearhead the development of its core asset, SNB-101, to treat pancreatic cancer.